№ 6 / 2012 / 15-21

УДК 617.51+617.53]-006.61-033.2:611-018.98:577.15:547.96

Авторы: Чойнзонов Е.Л.¹, Спирина Л.В.², Кондакова И.В.³, Чижевская С.Ю.⁴, Шишкин Д.А.⁵, Кульбакин Д.Е.⁶

кальпаины, плоскоклеточные карциномы головы и шеи., протеасома, транскрипционные факторы NF-B и HIF-1, фактор роста эндотелия сосудов

1. Абрамова Е.Б., Астахова Т.М., Ерохов П.А. и др. Множественность форм протеасомы и некоторые подходы к их разделению /// Изв. РАН. Сер. Биол. 2004. (2). 150-156.

2. Спирина Л.В., Кондакова И.В., Чойнзонов Е. Л. и др. Активность и субъединичный состав в плоскоклеточных карциномах головы и шеи // Бюл. эксперим. биол. мед. 2010. 149. (1). 89–92.

3. Спирина Л.В., Бочкарева Н.В., Кондакова И. В. и др. Регуляция инсулиноподобных факторов роста и NF-kB протеасомной системой при раке эндометрия // Молек. биол. 2012. 46. (3). 452–461.

4. Arlt A., Bauer I., Schafmayer C. et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) // Oncogene. 2009. 28. 3983–3996.

5. Baud V., Derudder E. Control of NF-kB activity by proteolysis // Curr. Top. Microbiol. Immunol. 2011. 349. 97–114.

6. Ben-Shahar S., Komlosh A., Nadav E. et al. 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate // J. Biol. Chem. 1999. 274. 21963–21972.

7. Chen C., Seth A.K., Aplin A.E. Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer // Mol. Cancer Res. 2006. 4. 695–707.

8. Chen Z., Ricker J.L., Malhotra P.S. et al. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms // Mol. Cancer Ther. 2008. 7. (7). 1949–1960.

9. Conner J.R., Smirnova I.I., Moseman A.P. et al. IRAK1BP1 inhibits inflammation by promoting nuclear translocation of NF-kB p50 // Proc. Natl. Acad. Sci. USA. 2010. 107. (25). 11477–11482.

10. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy // Biochem. Soc. Trans. 2007. 35. 12–17.

11. Goll D.E., Thompson V.F., Li H. et al. The calpain system // Physiol. Rev. 2002. 83. 731–801.

12. Hensley S.E., Zanker D., Dolan B.P. et al. Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses // J. Immunol. 2010. 184. (8). 4115–4122.

13. Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling // Immunol. Rev. 2006. 210. 171–186.

14. Jiang L.Z., Wang P., Deng B. et al. Overexpression of Forkhead Box M1 transcription factor and nuclear factor-κB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis // Hum. Pathol. 2011. 42. (8). 1185–1193.

15. Juvekar A., Manna S., Ramaswami S. et al. Bortezomib induces nuclear translocation of IkBα resulting in gene-specific suppression of NF-kB-dependent transcription and induction of apoptosis in CTCL // Mol. Cancer Res. 2011. 9. (2). 183–194.

16. Klatte T., Seligson D.B., Riggs S.B. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma // Clin. Cancer Res. 2007. 13. 7388–7393.

17. Li C., Li R., Grandis J. R. et al. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells //Mol. Cancer Ther. 2008. 7. (6). 1647–1655.

18. Li C., Chen S., Yue P. et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkB(a) degradation // J. Biol. Chem. 2010. 285. (21). 16096–16104.

19. Liang X., Yang D., Hu J. et al. Hypoxia inducible factor-1a expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma // Anticancer Res. 2008. 28. 1659–1666.

20. Linder C., Linder S., Munck-Wikland E. et al. Evaluation of tissue and serum VEGF in patients with head and neck carcinoma // Angiogenesis. 1999. 2. 365–372.

21. Lowry O., Rosebrough W., Farr A., Randall R. Protein measurement with folin phenol reagent // J. Biol. Chem. 1951. 193. 265–275.

22. Moorthy A.K., Savinova O.V., Ho J.Q. et al. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner // EMBO J. 2006. 25. (9). 1945–1956.

23. Reichart J., Welter C., Mitschele T. et al. Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin // J. Pathol. 2003. 199. (4). 509–516.

24. Ridge J.A., Glisson B.S., Lango M.N. et al. Head and neck tumors // Cancer management: 14^th edition. http://www.cancernetwork.com/cancer-management/head-and-neck/article/10165/1802498

25. Sandmann S., Prenzel F., Shaw L. et al. Activity profile of calpains I and II in chronically infarcted rat myocardium-influence of the calpain inhibitor CAL 9961 // Br. J. Pharmacol. 2002. 135. (8). 1951–1958.

26. Schmitz M.L., Bacher S., Kracht M. IkB-independent control of NF-kB activity by modulatory phosphorylations // Trends Biochem. Sci. 2001. 26. 186–190.

27. Spirina L.V., Yunusova N.V., Kolomiets L.A. et al. Association of growth factors, HIF-1 and NF-kB expression with proteasomes in endometrial cancer // Mol. Biol. Rep. 2012. 39. (9). 8655–8662.

28. Uden P., Kenneth N.S., Rocha S. Regulation of hypoxia-inducible factor-1a by NF-kB // J. Biochem. 2008. 412 (3). 477–484.

29. Voutsadakis I.A. Pathogenesis of colorectal carcinoma and therapeutic implications: the role of the ubiquitin-proteasome system and Cox-2 // J. Cell. Mol. Med. 2007. 11(2). 252–337.

30. Yan M., Xu Q., Zhang P. et al. Correlation of NF-κB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma // BMC Cancer. 2010. 10. 437.

31. Yue C.X., Ma J., Zhou H.J. The effect of RhoA and proteasome inhibitor MG132 on angiogenesis in tumors // Sichuan Da Xue Xue Bao Yi Xue Ban. 2011. 42. (4). 445–501.

Об авторах (для корреспонденции):